WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Subject: search.filters.subject.paclitaxel

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Successful treatment of pediatric post-liver transplant Kaposi's sarcoma with paclitaxel
    (TURKISH J PEDIATRICS, 2020-01-01) Sen, Hilal Susam; Ates, Belen Terlemez; Yilmazbas, Pinar; Ocak, Suheyla; Kirimlioglu, Hale; Gokce, Selim; Acarli, Koray
    Background. Kaposi's sarcoma (KS) is a complication of immunosuppressive therapy for transplant recipients. Unlike adult recipients, KS in pediatric organ transplantation is quite rare. Treatment is usually withdrawal of immunosuppression
  • Thumbnail Image
    Item
    Concurrent chemoradiotherapy with weekly carboplatin and paclitaxel may be a feasible option in inoperable stage III non-small cell lung cancer: a single center experience
    (CUKUROVA UNIV, FAC MEDICINE, 2019-01-01) Calikusu, Zuleyha; Sedef, Ali Murat; Saltaoglu, Pinar
    Purpose: Concurrent chemoradiotherapy (CCRT) is a standard treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). An optimal chemotherapy regimen with concurrent thoracic radiotherapy is not known. In this study, we investigated the efficacy and toxicity of CCRT with carboplatin {[}area under curve (AUC) 2] and paclitaxel (80 mg/m(2)) during CCRT. Materials and Methods: We performed a retrospective survival analysis using medical records of 40 patients with inoperable stage III NSCLC that were treated with concurrent chemoradiotherapy with carboplatin-paclitaxel (AUC 2, 60 mg/m2). Results: The most common histopathology was adenocarcinoma, which was diagnosed in 18 patients (45\%). There were 12 stage IIIA patients (30\%) and 28 stage IIIB patients (70\%). The median follow-up time was 22.5 months {[}95\% confidence interval (CI), 2.9-72.2]. Median disease-free survival (DFS) and overall survival (OS) were 22.5 months (95\% CI, 18.1-27.0) and 53.5 months (95\% CI, 23.5-82.8). Grade 3-4 hematological and non-hematological toxicities were seen in 8 (20\%) and 5 (12.5\%) patients, respectively. Conclusion: This study showed that CCRT with weekly carboplatin-paclitaxel provides similar outcomes to cases in the literature and the regimen seems to be feasible with a low rate of grade 3-4 toxicity during CCRT of non operable stage III NSCLC. Keywords: Carboplatin, non-small cell lung cancer, chemoradiotherapy, paclitaxel